{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:10:41Z","timestamp":1793427041113,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2458-11-203","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T18:54:39Z","timestamp":1302116079000},"source":"Crossref","is-referenced-by-count":31,"title":["Cost-effectiveness of different human papillomavirus vaccines in Singapore"],"prefix":"10.1186","volume":"11","author":[{"given":"Vernon J","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Kuie","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Leong","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Yin","family":"Tok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"2979_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Golbal cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322\/canjclin.55.2.74.","journal-title":"CA Cancer J Clin"},{"key":"2979_CR2","unstructured":"World Health Organization (WHO): Projections of mortality and burden of disease. [Accessed 29th July 2009], [\n                    http:\/\/www.who.int\/healthinfo\/global_burden_disease\/projections\/en\/index.html\n                    \n                  ]"},{"issue":"Suppl 12","key":"2979_CR3","doi-asserted-by":"publisher","first-page":"M60","DOI":"10.1016\/j.vaccine.2008.05.042","volume":"26","author":"SK Tay","year":"2008","unstructured":"Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH: Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine. 2008, 26 (Suppl 12): M60-70. 10.1016\/j.vaccine.2008.05.042.","journal-title":"Vaccine"},{"key":"2979_CR4","unstructured":"Health Promotion Board: Singapore. Health Programmes - Cervical Screen Singapore. [Accessed 27th July 2009], [\n                    http:\/\/www.hpb.gov.sg\/hpb\/default.asp?pg_id=1741\n                    \n                  ]"},{"key":"2979_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"Munoz N, Boasch FX, de Sanjose S, et al: Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 2003, 348: 518-27. 10.1056\/NEJMoa021641.","journal-title":"N Engl J Med"},{"key":"2979_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003, 16: 1-17. 10.1128\/CMR.16.1.1-17.2003.","journal-title":"Clin Microbiol Rev"},{"key":"2979_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","volume":"89","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Aguado T, et al: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003, 89: 101-5. 10.1038\/sj.bjc.6601024.","journal-title":"Br J Cancer"},{"issue":"49","key":"2979_CR8","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1016\/j.vaccine.2008.09.036","volume":"26","author":"W Techakehakij","year":"2008","unstructured":"Techakehakij W, Feldman RD: Cost-effectiveness of HPV vaccination compared with PAP smear screening on a national scale: a literature review. Vaccine. 2008, 26 (49): 6258-6265. 10.1016\/j.vaccine.2008.09.036.","journal-title":"Vaccine"},{"key":"2979_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3201\/eid1402.070499","volume":"14","author":"HW Chesson","year":"2008","unstructured":"Chesson HW, Ekwueme DU, Saraiya M, Markowtiz LE: Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008, 14: 244-51. 10.3201\/eid1402.070499.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"2979_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kohli M, Grima D, et al: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst. 2004, 96 (8): 604-615. 10.1093\/jnci\/djh104.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2979_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"359","author":"JJ Kim","year":"2008","unstructured":"Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine. 2008, 359 (8): 821-832. 10.1056\/NEJMsa0707052.","journal-title":"New England Journal of Medicine"},{"issue":"29","key":"2979_CR12","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","volume":"25","author":"M Brisson","year":"2007","unstructured":"Brisson M, Van de Valde N, De Wals P, Boily MC: Potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007, 25 (29): 5399-408. 10.1016\/j.vaccine.2007.04.086.","journal-title":"Vaccine"},{"key":"2979_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1478-7547-6-4","volume":"6","author":"SL Kulasingam","year":"2008","unstructured":"Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER: Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation. 2008, 6: 4-10.1186\/1478-7547-6-4.","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"8","key":"2979_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1471-0528.2008.01743.x","volume":"115","author":"EJ Dasbach","year":"2008","unstructured":"Dasbach EJ, Insinga RP, Elbasha EH: The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK. BJOG: an International Journal of Obstetrics and Gynaecology. 2008, 115 (8): 947-956. 10.1111\/j.1471-0528.2008.01743.x.","journal-title":"BJOG: an International Journal of Obstetrics and Gynaecology"},{"key":"2979_CR15","doi-asserted-by":"publisher","first-page":"a769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit M, Choi YH, Edmunds WJ: Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008, 337: a769-10.1136\/bmj.a769.","journal-title":"BMJ"},{"issue":"5","key":"2979_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1185\/030079908X297826","volume":"24","author":"TD Szucs","year":"2008","unstructured":"Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S: Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin. 2008, 24 (5): 1473-83. 10.1185\/030079908X297826. May","journal-title":"Curr Med Res Opin"},{"issue":"32","key":"2979_CR17","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1016\/j.vaccine.2008.05.038","volume":"26","author":"JJ Kim","year":"2008","unstructured":"Kim JJ, Kobus KE, Diaz M, et al: Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine. 2008, 26 (32): 4015-4024. 10.1016\/j.vaccine.2008.05.038.","journal-title":"Vaccine"},{"key":"2979_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/epirev\/mxj006","volume":"28","author":"EJ Dasbach","year":"2006","unstructured":"Dasbach EJ, Elbasha EH, Insinga RP: Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006, 28: 99-100. 10.1093\/epirev\/mxj006.","journal-title":"Epidemiol Rev"},{"issue":"1","key":"2979_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP: Model of assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007, 13 (1): 28-41. 10.3201\/eid1301.060438.","journal-title":"Emerg Infect Dis"},{"key":"2979_CR20","volume-title":"Complete Life Tables","author":"Singapore Department of Statistics","year":"2006","unstructured":"Singapore Department of Statistics: Complete Life Tables. 2006, [online]. [Accessed 15th April 2011], [\n                    http:\/\/www.singstat.gov.sg\/pubn\/popn\/lifetable06-09.pdf\n                    \n                  ] -2009 for Singapore Resident Population"},{"issue":"1","key":"2979_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.bjc.6603501","volume":"96","author":"M Kohli","year":"2007","unstructured":"Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, et al: Estimating the long-term impact of a prophylactic human papillomavirus 16\/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2007, 96 (1): 143-50. 10.1038\/sj.bjc.6603501.","journal-title":"Br J Cancer"},{"key":"2979_CR22","first-page":"165","volume":"4","author":"S Kulasingam","year":"2007","unstructured":"Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G: A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian. National Cervical Cancer Screening Program. Sexual Health. 2007, 4: 165-175.","journal-title":"National Cervical Cancer Screening Program. Sexual Health"},{"issue":"9686","key":"2979_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naup P, Salmeon J, Wheeler CM, Chow SN, Apter D, et al: Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374 (9686): 301-314. 10.1016\/S0140-6736(09)61248-4.","journal-title":"Lancet"},{"key":"2979_CR24","doi-asserted-by":"publisher","first-page":"F46","DOI":"10.1016\/j.vaccine.2008.02.039","volume":"26S","author":"RM Rogoza","year":"2008","unstructured":"Rogoza RM, Ferko N, Bentley J, et al: Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008, 26S: F46-F58. 10.1016\/j.vaccine.2008.02.039.","journal-title":"Vaccine"},{"key":"2979_CR25","doi-asserted-by":"publisher","first-page":"F16","DOI":"10.1016\/j.vaccine.2008.02.040","volume":"26S","author":"D Debicki","year":"2008","unstructured":"Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch CT, Anonychuk A, et al: Comparison of detailed and succinct cohort modeling approaches in the evaluation of cervical cancer vaccination. Vaccine. 2008, 26S: F16-F28. 10.1016\/j.vaccine.2008.02.040.","journal-title":"Vaccine"},{"key":"2979_CR26","doi-asserted-by":"publisher","first-page":"F29","DOI":"10.1016\/j.vaccine.2008.05.069","volume":"26S","author":"E Su\u00e1rez","year":"2008","unstructured":"Su\u00e1rez E, Smith JS, Bosch FX, et al: Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008, 26S: F29-F45.","journal-title":"Vaccine"},{"key":"2979_CR27","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c3493","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","unstructured":"FUTURE I\/II Study Group: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010, 341: c3493-10.1136\/bmj.c3493.","journal-title":"BMJ"},{"issue":"11","key":"2979_CR28","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006, 95 (11): 1459-66. 10.1038\/sj.bjc.6603469.","journal-title":"Br J Cancer"},{"issue":"2","key":"2979_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurpub\/ckp141","volume":"20","author":"A Dee","year":"2010","unstructured":"Dee A, Howell F: A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health. 2010, 20 (2): 213-9. 10.1093\/eurpub\/ckp141.","journal-title":"Eur J Public Health"},{"issue":"8964","key":"2979_CR30","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0140-6736(95)91086-7","volume":"345","author":"J Cuzick","year":"1995","unstructured":"Cuzick J, Szarewski A, Terry G, Ho L, et al: Human papillomavirus testing in primary cervical screening. Lancet. 1995, 345 (8964): 1533-6. 10.1016\/S0140-6736(95)91086-7.","journal-title":"Lancet"},{"issue":"7","key":"2979_CR31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/oxfordjournals.aje.a117485","volume":"141","author":"MT Fahey","year":"1995","unstructured":"Fahey MT, Irwig L, Macaskill P: Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995, 141 (7): 680-689.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"2979_CR32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1086\/597307","volume":"199","author":"DR Brown","year":"2009","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009, 199 (7): 926-35. 10.1086\/597307.","journal-title":"J Infect Dis"},{"key":"2979_CR33","volume-title":"Abstract presented at the 25th International Papillomavirus Conference (IPV)","author":"SR Skinner","year":"2009","unstructured":"Skinner SR, et al: Cross-protective efficacy of The bivalent vaccine\u2122 against oncogenic HPV types beyond HPV-16\/18. Abstract presented at the 25th International Papillomavirus Conference (IPV). 2009, Malmo, Sweden"},{"issue":"21-22","key":"2979_CR34","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.vaccine.2003.11.059","volume":"22","author":"DR Brown","year":"2004","unstructured":"Brown DR, Fife KH, Wheeler CM, Koutsky LA, et al: Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine. 2004, 22 (21-22): 2936-42. 10.1016\/j.vaccine.2003.11.059.","journal-title":"Vaccine"},{"issue":"9518","key":"2979_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1-virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized controlled trial. Lancet. 2006, 367 (9518): 1247-55. 10.1016\/S0140-6736(06)68439-0.","journal-title":"Lancet"},{"issue":"21","key":"2979_CR36","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al: A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med. 2002, 347 (21): 1645-51. 10.1056\/NEJMoa020586.","journal-title":"N Engl J Med"},{"issue":"1","key":"2979_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","volume":"107","author":"C Mao","year":"2006","unstructured":"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006, 107 (1): 18-27. 10.1097\/01.AOG.0000192397.41191.fb.","journal-title":"Obstet Gynecol"},{"issue":"27-28","key":"2979_CR38","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","volume":"24","author":"LL Villa","year":"2006","unstructured":"Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al: Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine. 2006, 24 (27-28): 5571-83. 10.1016\/j.vaccine.2006.04.068.","journal-title":"Vaccine"},{"issue":"9580","key":"2979_CR39","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch X, Naud P, Salmeron J, Wheeler CM: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with HPV types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet. 2007, 369 (9580): 2161-70. 10.1016\/S0140-6736(07)60946-5.","journal-title":"Lancet"},{"issue":"19","key":"2979_CR40","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"The FUTURE II Study Group","year":"2007","unstructured":"The FUTURE II Study Group: Quadrivalent vaccine against HPV to prevent highgrade lesions. N Engl J Med. 2007, 356 (19): 1915-27. 10.1056\/NEJMoa061741.","journal-title":"N Engl J Med"},{"key":"2979_CR41","volume-title":"Health Promotion Board, Singapore","author":"Health Promotion Board","year":"2002","unstructured":"Health Promotion Board: Abnormal Pap Smear & Preinvasive Disease of the Cervix. Health Promotion Board, Singapore. 2002"},{"key":"2979_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mob.2003.89","volume":"188","author":"H Wang","year":"2003","unstructured":"Wang H, Chia KS, Du WB, et al: Population-based survival for cervical cancer in Singapore, 1968-1992. Am J Obstet Gynecol. 2003, 188: 324-9. 10.1067\/mob.2003.89.","journal-title":"Am J Obstet Gynecol"},{"key":"2979_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/sti.76.3.162","volume":"76","author":"G Von Krogh","year":"2000","unstructured":"Von Krogh G, Lacey CJ, Gross G, et al: European course on HPV associated pathology: guidelines for primary case physicians for the diagnosis and management of anogenital warts. Sex Transm Infect. 2000, 76: 162-8. 10.1136\/sti.76.3.162.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"2979_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1071\/SH09145","volume":"7","author":"CK Fairley","year":"2010","unstructured":"Fairley CK, Donovan B: What can surveillance of genital warts tell us?. Sex Health. 2010, 7 (3): 325-7. 10.1071\/SH09145.","journal-title":"Sex Health"},{"issue":"8","key":"2979_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kohli M, Grima D, et al: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst. 2004, 96 (8): 604-615. 10.1093\/jnci\/djh104.","journal-title":"J Natl Cancer Inst"},{"issue":"No. 3","key":"2979_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1524-4733.1999.02203.x","volume":"2","author":"J Hay","year":"1999","unstructured":"Hay J, Jackson J: Methodological Issues in Conducting Pharmacoeconomic Evaluations--Modeling Studies. Value in Health. 1999, 2 (No. 3): 78-81. 10.1046\/j.1524-4733.1999.02203.x.","journal-title":"Value in Health"},{"issue":"2","key":"2979_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/jech.55.2.123","volume":"55","author":"L Bonneux","year":"2001","unstructured":"Bonneux L, Birnie E: The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health. 2001, 55 (2): 123-5. 10.1136\/jech.55.2.123.","journal-title":"J Epidemiol Community Health"},{"issue":"7","key":"2979_CR48","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2165\/00019053-200523070-00001","volume":"23","author":"JM Bos","year":"2005","unstructured":"Bos JM, Postma MJ, Annemans L: Disconting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics. 2005, 23 (7): 639-49. 10.2165\/00019053-200523070-00001.","journal-title":"Pharmacoeconomics"},{"issue":"7214","key":"2979_CR49","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bmj.319.7214.914","volume":"319","author":"DJ Torgenson","year":"1999","unstructured":"Torgenson DJ, Raftery L: Economic notes. Discounting. BMJ. 1999, 319 (7214): 914-5.","journal-title":"BMJ"},{"key":"2979_CR50","first-page":"18","volume-title":"Prevention Effectiveness- A Guide to Decision Analysis and Economic Evaluation","author":"AC Haddix","year":"2003","unstructured":"Haddix AC, Teutsh SM, Corso PS: Prevention Effectiveness- A Guide to Decision Analysis and Economic Evaluation. 2003, New York: Oxford University Press, 18-2","edition":"2"},{"key":"2979_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6963-10-11","volume":"10","author":"PH Liu","year":"2010","unstructured":"Liu PH, Hu FC, Lee PI, Chow SN, Huang CW, Wang JD: Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res. 2010, 10: 11-10.1186\/1472-6963-10-11.","journal-title":"BMC Health Serv Res"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-11-203\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-11-203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-11-203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-11-203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T20:10:47Z","timestamp":1548101447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-11-203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-11-203","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]},"article-number":"203"}}